Gilead Sciences (GILD) call put ratio 1 call to 1 put, FT says remdesivir failed in first trial
Tweet
Share
E-mail
Get Alerts GILD Hot Sheet
Price: $124.87 +0.90%
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 2.3%
Revenue Growth %: +4.4%
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 2.3%
Revenue Growth %: +4.4%
Join SI Premium – FREE
Gilead Sciences (NASDAQ: GILD) call put ratio 1 call to 1 put, FT says remdesivir failed in first trial
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Gilead Sciences (GILD) Reiterated at Overweight by Cantor Fitzgerald: Yeztugo Total TRx Down
- Amer Sports (AS) call put ratio 6.4 calls to 1 put with a focus on 4700 contracts of September 45 calls
- Perion Network (PERI) call put ratio 13.2 calls to 1 put with a focus on 6400 contracts of October 7.5 calls
Create E-mail Alert Related Categories
OptionsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
